SENIOR SCIENTIST
Ordway Research Institute

DIRECTOR
Virology Therapeutics and Pharmacodynamics Laboratory,
Ordway Research Institute

PROFESSOR
Biomedical Sciences,
School of Public Health,
State University at Albany

PROFESSOR EMERITUS
Center for Immunology
and Infectious Disease,
Albany Medical College

CONTACT
Virology Therapeutics and Pharmacodynamics Laboratory
Phone: (518) 641-6462
Fax: (518) 641-6304
jmcsharry@ordwayresearch.org

James J. McSharry, Ph.D.

Research Focus

Dr. McSharry has developed rapid, quantitative methods involving flow cytometry for measuring virus replication in virus-infected cells. He has used this technology to develop drug susceptibility assays for antiviral drugs effective against human immunodeficiency virus, herpes simplex viruses, cytomegalovirus, and influenza viruses. He is applying this technology to study the pharmacodynamics of antiviral drugs effective against human immunodeficiency virus, hepatitis C virus, and poxviruses.

The focus of the laboratory is to use a novel in vitro hollow fiber pharmacodynamic system and mathematical modeling to define the dosage and frequency of administration of antiviral drugs. Specifically, to design dosing strategies that optimize their effectiveness and minimize the probability that the infecting pathogens will become resistant to the antiviral agent during therapy. The mathematical modeling studies are carried out by Dr. George Drusano of the Ordway Research Institute.

Selected Publications (View)

• McSharry, JJ, MR Deziel, K Zager, Q Weng GL Drusano.  2009.  Pharmacodynamics of cidofovir for vacccina virus infection in an in vitro hollow-fiber infection model system.  Antimicrob. Agents Chemother. 53(1):129-35.
• Beauchemin CA, JJ McSharry, GL Drusano, JT Nguyen, GT Went, RM Ribeiro and AS Perelson.  2008.  Modeling amantadine treatment of influenza A virus in vitro.  J. Theor. Biol. 254 (2): 439-51.
• Paskaleva EE, X Lin, K Duus, JJ McSharry, JC Veille, C Thornber, Y Liu, DY Lee, M Canki.  2008.  Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase.  Virol. J. 15 (5): 5-8.
• McSharry, JJ, AC McDonough, BA Olson, and GL Drusano. 2004. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin. Diag. Lab. Immunol. 11:21-28.
• Chutkowski, C, B Olson, A McDonough, J Mahoney and JJ McSharry. 2002. Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates. Clin. Diag. Lab Immunol. 9:1379-1381.
• McSharry, JJ, A McDonough, B Olson, S Hallenberger, J Reefschlaeger, W Bender and GL Drusano. 2001. Susceptibilities of human cytomegalovirus clinical isolates to BAY-28-4766, BASY43-6965 and ganciclovir. Antimicrob Agents. Chemother. 45:2925-2927.
• McSharry, JJ, A McDonough, B Olson, C Talarico, M Davis, and KK Biron. 2001, Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benizimidazole L-riboside 1263W94. Clin. Diag. Lab Immunol. 8:1279-1281.
• McSharry, JJ, R Costantino, E Robbiano, R Echols, R Stevens, and JM Lehman. 1990. Detection and quantitation of human immunodeficiency virus-infected peripheral blood mononuclear cells by flow cytometry. J. Clin. Microbiol. 28:724-733.